Biosimilars Competition Act of 2018
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Jul 23, 2018)
Biosimilars Competition Act of 2018
This bill amends the Public Health Service Act to require a biologic manufacturer and a biosimilar drug manufacturer to provide notification to the Department of Justice and the Federal Trade Commission regarding certain pharmaceutical agreements. The agreements requiring notice are those related to the manufacturer, marketing or sale of the biosimilar product or the reference product.
Biosimilars are biological products approved by the Food and Drug Administration based on their similarity to an already-approved biological product.
What just happenedJul 27, 2018
Referred to the Subcommittee on Health.
Who’s behind it
- Introduced in HouseJul 23, 2018
- Jul 27, 2018Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Jul 23, 2018IntroReferralH11100
Referred to the House Committee on Energy and Commerce.
Energy and Commerce Committee - Jul 23, 2018IntroReferralIntro-H
Introduced in House
- Jul 23, 2018IntroReferral1000
Introduced in House